TL;DR
Alzheimer's slowly fills the brain with tangles of a protein called tau, and no drug that lowers tau has ever been approved for the disease. On Nov. 17, at the big Alzheimer's trials conference in Boston, Ionis and Biogen showed two years of results for an experimental drug built to turn the body's tau production down. The details, the numbers and our odds on what comes next are below the line. Subscribe to read them.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our labeled speculation on what it adds up to; and every source.



